Abstract
Background:Clinical trials in selected rheumatoid arthritis (RA) patient populations have shown possible benefits for Tumor Necrosis Factor inhibitors (TNFi’s) and Janus kinase inhibitors (JAKi’s) used in combination with csDMARDs over...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
